ALIM — Alimera Sciences Income Statement
0.000.00%
- $301.29m
- $360.44m
- $80.75m
- 37
- 33
- 89
- 51
Annual income statement for Alimera Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 53.9 | 50.8 | 59 | 54.1 | 80.8 |
Cost of Revenue | |||||
Gross Profit | 47.3 | 43.9 | 52 | 46.2 | 69.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 59.2 | 51.3 | 57.4 | 65.8 | 83.8 |
Operating Profit | -5.27 | -0.501 | 1.59 | -11.6 | -3.01 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -10.2 | -5.41 | -3.93 | -18.1 | -20 |
Provision for Income Taxes | |||||
Net Income After Taxes | -10.4 | -5.34 | -4.37 | -18.1 | -20.1 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -10.4 | -5.34 | -4.37 | -18.1 | -20.1 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -10.4 | -5.34 | -4.37 | -18.1 | -21.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.19 | -1.04 | -0.84 | -2.59 | -0.809 |